As inferred by enrichment of PIK3CA somatic mutation, clear cell carcinomas demonstrated superior sensitivities to PAM pathway inhibitors, including BKM120 (PI3K, P = 1.88 × 10−03) and AZD2014 (mTOR, P = 2.25 × 10−03). The gene discussed is MTOR; the disease is clear cell adenocarcinoma.